Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 4/20 | 0.63 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.55 |
| ▸ | KIT | P10721 | 2/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4966734 | 0.94 | PAK1 (0.62) | PAK1PDGFRBKITPDGFRAFLT3 | |
| SCHEMBL4966832 | 0.88 | PDGFRB (0.71) | PAK1PDGFRBKITPDGFRAFLT3 | |
| SCHEMBL14599462 | 0.88 | CCNC (0.50) | PAK1 | |
| SCHEMBL4967395 | 0.86 | PAK1 (0.55) | PAK1PDGFRBKITPDGFRAFLT3 | |
| SCHEMBL4969490 | 0.85 | PDGFRB (0.58) | PAK1PDGFRBKITPDGFRAFLT3 | |
| SCHEMBL4967242 | 0.84 | PAK1 (0.53) | PAK1PDGFRBKITPDGFRAFLT3 | |
| SCHEMBL4965795 | 0.83 | PDGFRB (0.66) | PAK1PDGFRBKITPDGFRAFLT3 | |
| SCHEMBL4965855 | 0.81 | PDGFRB (0.72) | PAK1PDGFRBKITPDGFRAFLT3 | |
| SCHEMBL4969355 | 0.81 | AKT1 (0.54) | PAK1PDGFRBKITPDGFRAFLT3 | |
| SCHEMBL4966726 | 0.80 | PDGFRB (0.54) | PAK1PDGFRBKITPDGFRAFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899319-A2 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1893206-A2 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| WO-2006135649-A2 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135636-A2 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281771-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281771-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | FLT3, CDC42BPG, PRKCQ | PAK1 133/4885MTNR1B 1754/4885PDGFRB 284/4885 |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | FLT3, BMX, ABL1 | PAK1 242/4885MTNR1B 647/4885PDGFRB 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.